Sinocare Showcases Its Comprehensive Diabetes Management Solutions at EASD

Vienna, Austria—September 15-19, 2025—The 61st Annual Meeting of the European Association for the Study of Diabetes (EASD 2025) was successfully held in Vienna, Austria. As one of the world’s largest and most influential clinical conferences in the field of endocrinology and diabetes, this year’s EASD brought together top experts and scholars from around the globe to discuss the latest advances in diabetes research, prevention, and clinical management technologies.

During the conference, Sinocare hosted an international industry symposium and an exclusive networking dinner, fully demonstrating the company’s professional expertise in diabetes management and its strong commitment to global scientific collaboration and industry innovation.

International Experts Applaud iCan CGM’s Exceptional Clinical Performance

Sinocare reaffirmed its commitment to providing informative, CGM-focused educational content to healthcare professionals worldwide. On the opening Monday of EASD 2025 in Vienna, Professor Lori Laffel, Dr. Guido Freckmann, and Professor Julia Mader were invited to share their research collaboration with iCanTM CGM. The symposium highlighted key themes 'Performance, Practicality, and Pediatrics,' and presented promising data from recent German and U.S. studies involving both adult and pediatric populations. Additionally, the session provided insights into initiating CGM systems in real-world settings, featuring expertise from a leading pediatric diabetes center. The discussion also explored the potential impact of diabetes technology on travel and employment opportunities for individuals with diabetes who have a passion for flying.

Image from EASD official coverage

Global Launch of iCan i6 CGM: Smarter Monitoring, Elevated Experience

Sinocare’s booth attracted a steady stream of visitors from over 20 countries. The next generation iCan i6 CGM system was the centerpiece of attention.

This new product builds on the hallmark features of the iCan series — 15-day accuracy and comfortable wear — and delivers multiple user experience upgrades: one-step application with a smaller, lighter sensor; 27-language support for global accessibility; built-in altitude compensation algorithm for reliable readings at high elevations; enhanced mobile app integration, enabling a seamless “effortless monitoring and globally accessible” experience.

At the same time, Sinocare’s exclusive partner in more than 20 European countries, A. Menarini Diagnostics s.r.l, showcased the co-branded GlucoMen® iCan CGM system at EASD. Menarini highlighted the iCan system’s latest features and clinical benefits through an immersive booth experience, drawing strong interest and engagement from medical professionals on-site.

From Prevention to Management: Building a Closed-Loop Diabetes Ecosystem

On September 15, Sinocare hosted a private dinner seminar, unveiling its new “A+C” Diabetes Prevention and Control Ecosystem to key partners. This innovative model integrates AGEscan non-invasive screening with CGM continuous glucose monitoring to enable early risk detection and precision intervention. Sinocare also introduced its hospital glucose management solution, which seamlessly connects outpatient and inpatient scenarios, achieving end-to-end digital glucose management and improving both efficiency and quality of care.

From cutting-edge CGM clinical research to integrated prevention and hospital management solutions, Sinocare’s presence at EASD 2025 showcased its deep integration of technological innovation with real-world patient and clinical needs. The company strengthened global collaborations with experts and partners, reaffirming its mission to advance diabetes care worldwide and deliver more comprehensive health protection for patients and healthcare providers alike.